Skip to main content
Optipharm.CO.,LTD logo

Optipharm.CO.,LTD — Investor Relations & Filings

Ticker · 153710 ISIN · KR7153710009 KO Professional, scientific and technical activities
Open in API
Filings indexed 177 across all filing types
Latest filing 2021-03-24 Declaration of Voting R…
Country KR South Korea
Listing KO 153710

About Optipharm.CO.,LTD

https://www.optipharm.co.kr

Optipharm is a biomedical company specializing in animal health solutions and advanced biotherapeutics. The company's core activities encompass animal disease diagnosis, the development and sale of veterinary pharmaceuticals, and the creation of bacteriophage-based treatments. A key focus is on preventative medicine, including the research and development of Virus-Like Particle (VLP) vaccines and a nanoparticle-based vaccine for Foot-and-Mouth Disease. In the biomedical sector, Optipharm is advancing xenotransplantation through its 'Medipig' platform for developing xenogeneic organs and tissues. The company also produces transgenic animal models for research and develops cell therapy products using animal stem cells, with a long-term strategy to transition its innovations to human medicine.

Recent filings

Filing Released Lang Actions
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled '정기주주총회결과' (Annual General Meeting Results) and provides a detailed breakdown of the resolutions passed during the meeting, including financial statement approval, director appointments, and remuneration limits. This aligns perfectly with the definition of a Declaration of Voting Results (DVA), which reports the official outcomes of shareholder votes at a general meeting.
2021-03-24 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 1% confidence The document is a regulatory filing titled '사외이사의 선임ㆍ해임 또는 중도퇴임에 관한 신고' (Report on the Appointment, Dismissal, or Resignation of Outside Directors). This document specifically details changes to the company's board of directors, which falls under the 'Board/Management Information' category.
2021-03-24 Korean
사업보고서 (2020.12)
Audit Report / Information Classification · 1% confidence The document is a comprehensive 'Audit Report' (감사보고서) for the company 'Optipharm' (주식회사 옵티팜) for the fiscal year 2020. It includes the independent auditor's report, financial statements (Statement of Financial Position, Statement of Comprehensive Income, Statement of Changes in Equity, Statement of Cash Flows), and detailed notes to the financial statements. It is not an Annual Report (10-K) as it focuses specifically on the audit and financial statements rather than the broader business activity report, and it is not an announcement (RPA) because it contains the full financial data. FY 2020
2021-03-16 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 1% confidence The document is a regulatory filing from a Korean company (Optipharm) disclosing a significant change in financial structure (revenue or profit/loss fluctuation of 30% or more). This is a standard regulatory disclosure requirement in the Korean market (DART system) for public companies to report material financial changes before the final audit is completed. It provides specific financial data and reasons for the variance, fitting the definition of a general regulatory filing. FY 2020
2021-03-09 Korean
주주총회소집결의
AGM Information Classification · 1% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for the company Optipharm. It outlines the date, location, agenda items (financial statements, director appointments, remuneration limits), and details regarding the appointment of an outside director. This document serves as the official proxy solicitation and information statement provided to shareholders to inform them of the upcoming meeting and the matters to be voted upon.
2021-03-09 Korean
주주총회소집공고
AGM Information Classification · 1% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Optipharm. It contains the meeting agenda, date, location, and details regarding voting rights and board activities. This document is a formal notice sent to shareholders to inform them of an upcoming meeting and to solicit their participation/votes. According to the provided definitions, this fits the 'Proxy Solicitation & Information Statement' (PSI) category, as it provides information and requests votes for the meeting.
2021-03-09 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.